Why Novo Nordisk surged 14% on new weight-loss drug results
Novo Nordisk shares jump close to 14% on promising trial results for amycretin, a once-weekly obesity drug, signaling fierce ...
Benzinga.com7d
Novo Nordisk's Weekly Amycretin Delivers Up to 22% Weight Loss in Study, Stock Soars
Get the Real Story Behind Every Major Earnings Report On Friday, Novo Nordisk A/S NVO released topline results from a phase 1b/2a trial with amycretin intended for once-weekly subcutaneous ...
Pharmabiz3d
Novo Nordisk announces positive results from phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity
Novo Nordisk, a leading global healthcare company, announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once weekly ...
BioSpace6d
Novo Rebounds as Next-Gen Obesity Drug Elicits up to 22% Weight Loss
The readout comes on the heels of CagriSema’s disappointing Phase III performance, where it missed Novo’s projection of 25% ...
MedCity News5d
Novo Nordisk Obesity Drug Shows 22% Weight Loss, But Lack of Safety Detail Is a Sticking Point
The drug, amycretin, is a peptide designed to bind to and activate both the GLP-1 and amylin receptors. Novo Nordisk is developing the molecule for the treatment of obesity and type 2 diabetes ...
Novo Nordisk shares pop 9% on early-stage weight loss drug trial results
The Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.
Business Insider7d
Novo Nordisk amycretin data helps rebut concerns, says BofA
After Novo Nordisk (NVO) reported that subcutaneous amycretin demonstrated up to 22% absolute weight loss at 36-weeks in a Phase 1/2a trial, BofA thinks this “looks potentially best in class.” ...
MM&M7d
Novo Nordisk’s amycretin cuts weight by 22% in early obesity trial
Just over a month after its CagriSema readout disappointed analysts, Novo Nordisk released promising data for its obesity drug amycretin. The Danish pharmaceutical giant ended off the week on a high ...
Yahoo Finance6d
Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity
Novo Nordisk A/S Bagsværd, Denmark, 24 January 2025 – Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor ...
Yahoo Finance6d
Novo Nordisk's Weekly Amycretin Delivers Up to 22% Weight Loss in Study, Stock Soars
On Friday, Novo Nordisk A/S (NYSE:NVO) released topline results from a phase 1b/2a trial with amycretin intended for once-weekly subcutaneous administration. The trial investigated the safety ...
NBC New York6d
Novo Nordisk shares pop on early-stage weight loss drug trial results
Shares of Novo Nordisk jumped Friday after the Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug. The trial showed average weight ...
PharmiWeb4d
Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity
Bagsværd, Denmark, 24 January 2025 – Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once ...